Company intelligence / Profile preview

Nafas

Ownership: Private
Development stage: Other

Overview

Nafas Zist Pharmed, founded in 2019, focuses on developing and manufacturing high-tech inhalation drugs—specifically dry powder inhalers—for respiratory conditions. The company has received regulatory approval for its first product after extensive R&D and collaborates with domestic and international academic centers. It emphasizes innovation in drug formulation, particle engineering, and nano-drug production to improve patient health outcomes.

Therapeutic areas: Pulmonology
Modalities: Small moleculeNanoparticleDevice
Industry: Biotech

Partnerships

Collaborates with domestic and foreign academic/scientific centers but no specific companies named.

Beyond the preview

Go deeper on Nafas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nafas.

Explore the full profile